<DOC>
	<DOCNO>NCT01053728</DOCNO>
	<brief_summary>Primary Objective : - To establish initial safety/tolerability pharmacodynamic pharmacokinetic profile four formulation SAR161271 patient T1DM . Secondary Objective : - To establish relative potency SAR161271 compare insulin glargine patient T1DM</brief_summary>
	<brief_title>Study How Single Rising Doses SAR161271 Are Absorbed Act Patients With Type 1 Diabetes Mellitus ( T1DM )</brief_title>
	<detailed_description>The total per patient 31 67 day ; include post-study visit 108 172 day . In case additional late post-study visit last dosing , approximately 213 279 day , broken follow : - Screening : 3 27 day ; - Treatment Periods 1 day institutionalisation Day -1 Day 3 ; - Wash-out dos : 7 10 day ; - End Study visit : 7 10 day last dose . - Post-study visit 84 112 day last dosing . If necessary , additional post-study visit 6 7 month last dosing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients type 1 diabetes mellitus ( T1DM ) define American Diabetes Association average total insulin dose &lt; 1.2 U/kg/day Fasting negative serum Cpeptide ( &lt; 0.3 nmol/L ) Glycated hemoglobin ( HbA1c ) &lt; = 9 % Stable insulin regimen least 2 month study Body weight 50110 kg inclusive ; body mass index 1830 kg/m2 , inclusive Certified healthy T1DM comprehensive clinical assessment Exclusion criterion : Any history presence clinically relevant ( T1DM ) cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , psychiatric , systemic , ocular , infectious disease , sign acute illness , major diabetic complication diabetic retinopathy . Blood donation , volume , within 1 month inclusion . Presence history drug hypersensitivity , allergic disease diagnose treated physician Regular use medication insulin last month study start exception thyroid hormone , metformin , lipidlowering antihypertensive drug Positive reaction follow test : hepatitis B surface ( HBs ) antigen , antihepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus ( HIV ) 1 antibody , antiHIV2 antibody . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>